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In recent years much more attention has been paid to 
postnatal mental illness and to its possible effects on the 
baby than to antenatal mental disorder and its effects on 
foetal development. 1 It is now generally accepted that 
most women do not conform to the stereotype of the 
woman who blooms with health in pregnancy.2 Observers 
have commented on the apparent high prevalence of 
psychiatric symptoms in pregnancy. Studies of antenatal 
depression offer certain advantages. The time perimeter 
is limited to the pregnancy, easing comparisons between 
studies. Furthermore women can easily be recruited since 
pregnancy is a time of high medical contact. 
Incidence and prevalence of antenatal 
depression 
Studies on the incidence of antenatal depression have 
revealed that it is higher than previously thought. O'Hara 
found that 9% of pregnant women have illnesses that fulfil! 
the Research Diagnostic criteria for depression.1 Similarly, 
Scholle screened obstetric patients at random for depressive 
symptoms and found that 20% met criteria for a diagnosis 
of depression.4 It is now believed that pregnancy is a risk 
factor for a mood disorder especially in those with a history 
of depressive illness ,s and untreated antenatal depression 
may be associated with 50-62% of postpartum episodes 
and a worsening of the psychiatric condition.6,7 
Variables associated with antenatal depression 
It is important to identify the causes of prenatal depression. 
Most of the studies carried out found an association with 
psychosocial factors. Depression during pregnancy is 
associated with being younger, less educated, having a 
greater number of children and being a home maker8, 
previous termination of pregnancy, having serious doubts 
about having the baby, having anxieties about the foetus2, 
having an unwanted pregnancy and a negative psychological 
response to the news of the pregnancy by the woman and 
husband.9 Evidence of personal past psychiatric disturbance 
in the mother, premorbid neurotism, marital conflict and 
lack of support were also associated with antenatal 
depression. 2 
Effects of antenatal depression 
Depression in the antenatal period is usually missed. 
Depressed women are not good antenatal attendees. 
Depressive symptoms were associated with poor weight 
gain and may have caused poor health behaviour such as 
cigarette smoking, alcohol and drug abuse 10 Antenatal stress 
and smoking contributed independently and significantly 
to a lower gestational age, lower birth weight and smaller 
head circumference when corrected for birth weight. 11 
Prenatal stress also worsened the scores on the neonatal 
neurological examination. 
Antenatal depression may cause ill adjustment to 
pregnancy and is also likely to affect the course of 
pregnancy. The effect can also be on the physical welfare 
of the foetus. Behavioural responses may be developed 
by the foetus from quite early in gestation. Studies found 
that the foetus could mount its own hormonal and other 
stress responses from at least mid-gestation. The 
mechanism for transmission of maternal stress on the 
foetus is not known. Possible mechanisms described 
include constriction of the uterine artery 'by maternal 
stress hormones causing impaired blood flow to the baby, 
which in turn generates a foetal stress response. 12 Also 
certain hormones are transmitted in sufficient amount to 
the foetus to have a direct effect. 13 Despite the prevalence 
of depression during pregnancy and the amount of 
literature associated with its treatment, whether 
pharmacological or otherwise, large numbers of women 
are untreated. In one study, one in five pregnant women 
experienced depression but few sought treatment. 14 Such 
studies conclude that the stigma of having depression 
during pregnancy may prevent women from seeking 
active treatment - women may feel guilty for suffering 
during what is supposed to be a happy period. 
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Managemen of mood 
disorders during pregnancy 
The most important issue in the 
management of mood disorders during 
pregnancy is that they are actively. 
managed. Recognition of depressIve 
symptoms during pregnancy, in 
practice frequently means that although 
recognized, they are not treated. 
Antidepressant medication is indicated 
for severe depressions: these are 
unlikely to respond to talking therapies. 
Clinicians should discuss the 
possibility of pregnancy and 
parenthood with all women of 
reproductive years who have a history 
of mood disorder, regardless of 
whether they plan to have a family 
imminently or not. Most pregnancies 
are unplanned and such discussions 
may prevent abrupt discontinuation of 
medication. 
The primary concerns regarding 
use of psychotropic medications 
during pregnancy and lactation 
include physical or neurobehavioral 
teratogenesis in the fetus, neonatal 
toxicity, and neonatal withdrawal. 
Of particular importance during 
pregnancy is that polypharmacy 
should be avoided if possible. 
Besides, medications should be 
titrated to the minimum effective 
dose. 
It can be a difficult challenge to 
determine the correct therapeutic 
dose of medication during 
pregnancy. Pregnancy alters the 
pharmokinetics of psychotropic 
medications producing effects such 
as decreased gastric acid and 
gastrointestinal emptying,15 
increased extracellular fluid volume 
and body fat, changes in intrahepatic 
(P450 system) and extrahepatic 
activity 16 and increased glomerular 
filtration rate and renal blood flow. 17 
Due to these pharmacokinetics 
changes, clinicians should closely 
monitor patients, particularly during 
the third trimester and the 
postpartum to ensure adequate 
dosing of medications. 
ArrUtriptylene and imipramine are 
the recommended drugs of choice for 
the treatment of depression during 
pregnancy, based on the length of time 
that they have been in use and the 
cumulative data on their lack of 
foetotoxicity. However in reality, 
SSRIs are frequently prescribed during 
pregnancy as they are the drugs of 
choice for most psychiatrists and 
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family doctors outside of pregnancy 
and there is cumulative positive 
evidence about safety to the foetus . 
Fluoxetine has been extensively 
studied in pregnancy and data showed 
no increase in either the incidence of 
malformations or spontaneous 
abortions.18 Although there are less 
reprotoxicology data available on 
citalopram, fluvoxamine and sertraline 
there is no clear evidence of an 
increased risk of foetal toxicity or other 
pregnancy complications so far. 18,19 
Neonatal withdrawal symptoms may 
occur following chronic use of any 
antidepressant or their use near the 
time of delivery. Therefore if clinically 
appropriate, the dose of the 
antidepressant should be tapered 3-4 
weeks prior to the expected date of 
delivery to minimize withdrawal 
symptoms. 8J 
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